Disproportional response: a small company's current business is visibly outgrowing its own size
The model's full reasoning — Q2 2017 call → NOWe need to determine if management conveys that the business currently happening is disproportionately large relative to the company's size. The transcript shows a company that has made acquisitions, has revenue of $104M, and is guiding $114-118M. They discuss various product ramps, but do they explicitly state that current activity is large relative to their small size? They mention "commenced production shipments" of a 28nm microwave backhaul transceiver, "commenced volume production shipments" of a 20Gbps millimeter wave backhaul modem to a Tier 1 Chinese OEM, "commenced shipments" of MOCA 2.5, etc. But they don't explicitly contrast the scale of these with the company's size. They talk about growth and diversification, but not about being small relative to what's arriving. They mention "we are uniquely positioned" and "strong design traction" but that's not the same as saying the current business is disproportionately large. They also discuss optical weakness and satellite lumpiness. There's no explicit statement like "this single customer could double our revenue" or "we are handling volumes that would have been out of reach." The closest might be that they have a "secular design win for G.Now last mile access at a major telco operator in Asia, which will ramp to revenues in the second half of 2018" - but that's future, not current. They also mention "we have commenced shipments" but without quantifying relative to size. The question asks if management conveys that the business they are doing RIGHT NOW is visibly outgrowing the company's own current size. They don't seem to make that explicit. They talk about growth and opportunities, but not about disproportion. So answer NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| KOPN | Kopin Corporation | Q4 2023 | 2024-03-14 | C+ |
| TMCI | Treace Medical Concepts, Inc. | Q2 2022 | 2022-08-13 | B+ |
| VNRX | VolitionRx Limited | Q1 2022 | 2022-05-12 | F |
| FLUX | Flux Power Holdings, Inc. | Q2 2022 | 2022-02-10 | D |
VNRX · Q1 2022 → YESThe question is: Does management convey that the business the company is doing RIGHT NOW is visibly outgrowing the company's own current size and setup? That current activity, demand, or commitments a...YES The transcript shows management explicitly describing the Heska deal (already signed and with $10M upfront received) as a long-term, multi-year commitment that will generate ongoing kit/component revenue "significantly greater" than the $28M milestones, with "millions of tests" expected each year — all while repeatedly noting the company is "not a big company" and that this is "the beginning of our commercial journey" after 12 years of R&D. They contrast this with their tiny current revenue ($114k) and cash position, framing the new activity as disproportionately large relative to their size.
TMCI · Q2 2022 → YESThe question is: Does management convey that the business the company is doing RIGHT NOW is visibly outgrowing the company's own current size and setup? That current activity, demand, or commitments a...YES Management explicitly describes the business as outgrowing its current setup in present-tense terms: they are “once again in the process of relocating to a larger headquarters facility” to meet “increased requirements” for training, R&D, warehousing, and infrastructure; the direct sales force has grown 52% to 123 quota-carrying reps and is already trending above the year-end 70% direct mix goal; surgeon penetration has reached 20% of the estimated 10,000 U.S. foot-and-ankle surgeons while procedure penetration is 4.6% of the 450,000 annual U.S.
KOPN · Q4 2023 → YESThe question is: Does management convey that the business the company is doing RIGHT NOW is visibly outgrowing the company's own current size and setup? That current activity, demand, or commitments a...YES The transcript shows management describing current activity (a $55 million backlog, a $20.5 million new order, follow-on orders, and tripled weapon-site volume expected in 2024) as large relative to the company’s still-small size and setup. They explicitly note the backlog is a “record level 10 years,” that they had to extend the holiday shutdown and retool the plant for a “significant increase in production,” and that they are “buying to that level of volume today” while remaining conservative on guidance.